in The News - News & Events

February 15, 2013

Cambridge biotech has formula for success

January 10, 2013

Genomeweb.com -- Epizyme Taps Roche to Develop Cobas 4800 CDx for Epizyme/Eisai Lymphoma Drug Candidate

November 5, 2012

Chemical & Engineering News -- Advancing R&D By Venture Philanthropy

October 18, 2012

SciBx -- EZH2 moves

September 28, 2012

MIT Tech Review -- Pharmaceutical Firms Widen Search for Medicines

September 28, 2012

USA Today -- Biotech/Personalized Health Publication

September 20, 2012

Partnering360 -- Interview with Jason Rhodes of Epizyme

July 6, 2012

Nature Reviews Drug Discovery -- Epizyme–Celgene Deal Signals Interest in New Class of Epigenetic Drugs

June 8, 2012

Drug Discovery News -- Two Down, 94 To Go

May 24, 2012

In Vivo -- Epizyme Builds a Cancer Company at Mach Speed

May 18, 2012

Pharmacogenomics Reporter -- With Celgene Partnership Epizyme Hopes to Accelerate Personalized Epigenetic Drug Development

May 1, 2012

partneringNews -- Epizyme: Intensive Dealmaking in Pursuit of Personalized Therapeutics

April 26, 2012

Pink Sheet -- Celgene Licenses Lead Program from Epizyme, Takes Option to Remaining Pipeline

April 26, 2012

FierceBiotech -- Epizyme builds epigenetics lineup with $90M Celgene score

April 26, 2012

Xconomy -- Epizyme Gets $90M in Epigenetics Partnership with Celgene

April 26, 2012

C&EN Blog -- Epizyme & Celgene to Develop Epigenetics-Based Cancer Drugs

April 16, 2012

C&EN -- Cover by Lei Jin, Ph.D.: Companies Make Headway in Understanding Epigenetic Targets and Designing Drugs to Modulate Them

April 12, 2012

From the Trenches: Q&A with a Local Biotechnology Chief Business Officer Boston Biotech Conferences: BD Biotech April 12, 2012

December 6, 2011

Xconomy -- It Takes a Village to Raise a Biotech Startup: Highlights from the Tweetchat

September 8, 2011

FierceBiotech -- Epizyme - 2011 Fierce 15

September 8, 2011

Nature Chemical Biology -- Targeting Leukemia on the DOT

August 26, 2011

F1000 -- 2000 Posters And Counting...

August 17, 2011

Cancer Discovery -- DOT1L Is a Therapeutic Target in Mixed-Lineage Leukemia

August 4, 2011

SciBx -- Epizyme Connects the DOTs

June 13, 2011

BioWorld Today -- First In Vivo Data for HMT Inhibitors,
Epigenetic Approach Works for Mixed-Lineage Leukemia

June 1, 2011

The Wall Street Journal -- Biotech VCs No Longer in a "Field Of Dreams"

May 1, 2011

The Scientist -- Epizyme Named #1 Worldwide "Best Places to Work, Industry 2011" Survey

April 22, 2011

Chemistry & Biology -- Epizyme: Plying the Epigenome's Enzymes

April 2011

Life Science Leader -- Founded on Research That... "Brought The House Down"

March 29, 2011

Xconomy Boston -- Epizyme, Riding High on Two Big Pharma Deals, Zeroes in on Personalized Cancer Therapy

March 28, 2011

BioCentury -- Epigenetic Edge

January 10, 2011

Xconomy Boston -- Epizyme Nabs $650M Deal with Glaxo to Hunt for Epigenetic Drugs

December 9, 2010

SciBx -- EZH2 Does It

November 2010

Start-Up -- A Groundswell in Epigenetics

November 24, 2010

BioWorld Today -- For Epigenetic Enzyme, 1+1 Makes Three Methyl Groups

November 16, 2010

The Scientist -- Unusual Cancerous Allies

August 30, 2010

BioCentury, The Bernstein Report on Biobusiness -- Epizyme: Expanding Epigenetics

May 21, 2010

Transforming Cancer Therapy via HMT Inhibition, MSA Partners, Japan (English)

Transforming Cancer Therapy via HMT Inhibition, MSA Partners, Japan (Japanese)

November 23, 2009

Epizyme Featured by BusinessWeek as One of the Most Innovative New Start-ups